There are plenty of evidences to support it: Rollin et al. found that ID2 may be developed as the biomarker for the prognosis of poorly differentiated tumors as it is associated with dedifferentiation [5]; Li et al. demonstrated that ID1 may activate the NF-kappa B signaling pathway to promote the process of proliferation, migration, and invasion in NSCLC cells [66]; Qi et al. found that ID4 impacted on the p38 MAPK pathway to inhibit cisplatin-induced apoptosis [67]. Here, ID2 is linked to non-small cell lung carcinoma.